A Prospective Care-Compliant Case Series on Withania Coagulans Monotherapy in Patients with Type 2 Diabetes Mellitus

Abstract

Withania coagulans Dunal is described in Ayurvedic literature for the management of Madhumeha, yet systematically documented clinical evidence in Type 2 diabetes mellitus (T2DM) remains limited despite supportive preclinical data. This prospective, single-centre case series evaluated the clinical effects and safety of Withania coagulans fruit powder administered as Ekala Dravya (single-drug) monotherapy over 60 days in 23 patients with T2DM. Authenticated dried fruit powder was given orally at a dose of 5g twice daily before meals. Glycaemic parameters, including fasting blood sugar (FBS) and postprandial blood sugar (PPBS), were assessed at baseline, day 30, and day 60, along with anthropometric and laboratory safety parameters. All participants completed the study with good compliance. Mean FBS decreased from 151.83±26.10mg/dL at baseline to 87.73±10.86mg/dL at day 60 (p<0.0001), while mean PPBS decreased from 220.00±50.46mg/dL to 111.91±19.01mg/dL (p<0.0001). A modest but significant reduction in body weight and body mass index was observed. No adverse events were reported, and haematological, hepatic, and renal parameters remained within normal limits. These findings suggest that Withania coagulans monotherapy may provide effective short-term glycaemic control with good tolerability in T2DM, warranting further evaluation through controlled clinical studies.